SAMHD1 and acute myeloid leukemia: Next, we investigated the impact of SAMHD1 deficiency on DAC activity by different approaches: (i) CRISPR–Cas9-mediated SAMHD1 gene disruption in AML cell lines exhibiting high endogenous SAMHD1 levels, (ii) SAMHD1 knockdown using lentiviral vectors encoding shRNA, or (iii) targeted degradation of SAMHD1 with virus-like particles (VLPs) that shuttle the SAMHD1-interacting lentiviral Vpx protein (Vpx-VLPs) into cells19.